The mechanisms responsible for the reduction in CD9 expression often observed during cancer progression are currently unknown; however there are many miRNAs that are predicted to regulate the CD9 3′UTR, and the RNA-binding protein, HuR, has been shown to differentially regulate CD9 mRNA stability in different breast cancer cell lines [29]. This evidence concerns the gene ELAVL1 and cancer.